Educational information only. Not medical advice, not a diagnosis, and not an offer to sell any product. These are experimental or unapproved substances; we do not provide dosage, sourcing, or use guidance. Consult a licensed clinician. We link to official sources only.
A laboratory-made peptide of 15 amino acids, derived from a sequence found in gastric juice. It is not a component of any approved drug and has no USP monograph. Most published data comes from animal models.
Heavily promoted in fitness and recovery communities as a repair aid, often paired with TB-500. It is scheduled for review at the FDA's July 23, 2026 compounding advisory committee meeting.
| Claim | Strongest evidence |
|---|---|
| Gut / ulcerative colitis | R Regulatory only |
| Tendon / injury recovery | C Animal |
| General anti-inflammatory | C Animal |
FDA staff stated BPC-157 is not a component of an approved drug, has no USP monograph, and proposed not adding it to the 503A list, citing characterization, safety, immunogenicity, and effectiveness gaps. It is prohibited in sport (WADA/USADA).
No well-designed human trials establish safety or efficacy. Animal results do not transfer to humans. Injectable use raises immunogenicity and impurity concerns. Athletes face anti-doping sanctions.
No. It is an unapproved drug; FDA staff proposed not adding it to the 503A compounding list.
Very little. Published human data is limited to small or unsubmitted studies; most evidence is from animals.
No. It is prohibited by anti-doping authorities.
Choose your main interest, then get one email when regulatory status changes or strong new evidence lands. Health topics only. Unsubscribe anytime.
Educational information only. Not medical advice, not a diagnosis, and not an offer to sell any product. These are experimental or unapproved substances; we do not provide dosage, sourcing, or use guidance. Consult a licensed clinician. We link to official sources only.